A vaccine targeting human IL-4 and IL-13 protects against asthma in humanized mice

Allergy. 2023 Jul;78(7):2028-2031. doi: 10.1111/all.15680. Epub 2023 Mar 1.

Authors

Emma Lamanna^{1

2}, Eva Conde^{1

2

3}, Aurélie Mougel^{2

4}, Jonathan Bonnefoy², Fabien Colaone², Ophélie Godon¹, Samir Hamdi², Jasper B J Kamphuis⁴, Béatrice Drouet², Vincent Serra², Pierre Bruhns¹, Laurent L Reber^{2

4}

Affiliations

¹ Institut Pasteur, Université de Paris Cité, Inserm UMR 1222, Unit of Antibodies in Therapy and Pathology, Paris, France.
² Neovacs SA, Suresnes, France.
³ Sorbonne Université, College Doctoral, Paris, France.
⁴ Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.

PMID: 36799426
DOI: 10.1111/all.15680

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Asthma* / prevention & control
Humans
Interleukin-13
Interleukin-4
Mice
Mice, Inbred BALB C
Vaccines*

Substances

Interleukin-13
Interleukin-4
Vaccines

Grants and funding

ERC_/European Research Council/International